Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Clinical trial NCT05618301 · COMPLETED
Trial details
- NCT number
- NCT05618301
- Sponsor
- Washington University School of Medicine
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-07
- Primary completion
- 2025-06-24
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.